Alexion Pharmaceuticals Given Consensus Rating of “Buy” by Analysts (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) have earned a consensus recommendation of “Buy” from the twenty-two ratings firms that are currently covering the stock, American Banking News reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $159.61.
In other Alexion Pharmaceuticals news, CFO Vikas Sinha sold 3,552 shares of the company’s stock on the open market in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $154.47, for a total value of $548,677.44. Following the sale, the chief financial officer now directly owns 129,775 shares in the company, valued at approximately $20,046,344. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 3.10% during mid-day trading on Monday, hitting $168.699. The stock had a trading volume of 586,716 shares. Alexion Pharmaceuticals has a 52 week low of $81.82 and a 52 week high of $169.98. The stock’s 50-day moving average is $139. and its 200-day moving average is $121.0. The company has a market cap of $33.137 billion and a price-to-earnings ratio of 128.84.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, January 30th. The company reported $0.87 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. Analysts expect that Alexion Pharmaceuticals will post $3.87 EPS for the current fiscal year.
A number of research firms have recently commented on ALXN. Analysts at Deutsche Bank raised their price target on shares of Alexion Pharmaceuticals from $125.00 to $205.00 in a research note to investors on Monday. Separately, analysts at Zacks upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday. They now have a $189.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday, February 4th. They now have a $170.00 price target on the stock.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.